Candel therapeutics appoints dr. francesca barone as chief scientific officer

Needham, mass., feb. 03, 2022 (globe newswire) -- candel therapeutics, inc. (nasdaq: cadl), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that francesca barone, m.d., ph.d., has been named as the company's chief scientific officer.
CADL Ratings Summary
CADL Quant Ranking